Your browser doesn't support javascript.
loading
Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
Maura, Francesco; Bolli, Niccoló; Angelopoulos, Nicos; Dawson, Kevin J; Leongamornlert, Daniel; Martincorena, Inigo; Mitchell, Thomas J; Fullam, Anthony; Gonzalez, Santiago; Szalat, Raphael; Abascal, Federico; Rodriguez-Martin, Bernardo; Samur, Mehmet Kemal; Glodzik, Dominik; Roncador, Marco; Fulciniti, Mariateresa; Tai, Yu Tzu; Minvielle, Stephane; Magrangeas, Florence; Moreau, Philippe; Corradini, Paolo; Anderson, Kenneth C; Tubio, Jose M C; Wedge, David C; Gerstung, Moritz; Avet-Loiseau, Hervé; Munshi, Nikhil; Campbell, Peter J.
Afiliação
  • Maura F; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bolli N; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Angelopoulos N; Department of Medical Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Dawson KJ; Department of Medical Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Leongamornlert D; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Martincorena I; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Mitchell TJ; School of Computer Science and Electronic Engineering, University of Essex, Colchester, UK.
  • Fullam A; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Gonzalez S; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Szalat R; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Abascal F; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Rodriguez-Martin B; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Samur MK; European Bioinformatics Institute, European Molecular Biology Laboratory (EMBL-EBI), Hinxton, UK.
  • Glodzik D; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Roncador M; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Fulciniti M; CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela, Santiago de Compostela, Spain.
  • Tai YT; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Minvielle S; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Magrangeas F; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Moreau P; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
  • Corradini P; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Anderson KC; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Tubio JMC; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
  • Wedge DC; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
  • Gerstung M; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
  • Avet-Loiseau H; Department of Medical Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Munshi N; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Campbell PJ; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nat Commun ; 10(1): 3835, 2019 08 23.
Article em En | MEDLINE | ID: mdl-31444325
ABSTRACT
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using sequences from 67 MM genomes serially collected from 30 patients together with public exome datasets. Bayesian clustering defines at least 7 genomic subgroups with distinct sets of co-operating events. Focusing on whole genome sequencing data, complex structural events emerge as major drivers, including chromothripsis and a novel replication-based mechanism of templated insertions, which typically occur early. Hyperdiploidy also occurs early, with individual trisomies often acquired in different chronological windows during evolution, and with a preferred order of acquisition. Conversely, positively selected point mutations, whole genome duplication and chromoplexy events occur in later disease phases. Thus, initiating driver events, drawn from a limited repertoire of structural and numerical chromosomal changes, shape preferred trajectories of evolution that are biologically relevant but heterogeneous across patients.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Genoma Humano / Carcinogênese / Modelos Genéticos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Genoma Humano / Carcinogênese / Modelos Genéticos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos